Susceptibility to neuroleptic-induced parkinsonism--age and increased substantia nigra echogenicity as putative risk factors

Eur Psychiatry. 2003 Jun;18(4):177-81. doi: 10.1016/s0924-9338(03)00045-2.

Abstract

Objective: Patients treated by neuroleptics often develop neuroleptic-induced parkinsonism (NIP) to a varying extent. The reasons for this are discussed controversially in the literature. Previous transcranial sonography (TCS) findings of the substantia nigra (SN) in patients with idiopathic Parkinson's disease suggest a correlation of echogenicity with nigrostriatal dysfunction.

Method: One hundred psychiatric patients receiving neuroleptics were included. They underwent clinical examination for NIP (Simpson and Angus-scale) and, independently, TCS of the SN. History of smoking habits and medication were taken from the patient's chart.

Results: We found a significant positive association of the prevalence of NIP with age (P < 0.01) and the echogenic area of the SN (P < 0.05). Neither type nor dosage of the neuroleptics was found to have any significant impact on the occurrence of NIP. Smokers displayed lower prevalence of NIP (P < 0.05) and lower EPS scores (P < 0.01).

Conclusions: These findings suggest that age and increased size of SN echogenicity are possible risk factors for NIP. In contrast, smoking seems to have a certain protecting effect.

MeSH terms

  • Adult
  • Aged
  • Antipsychotic Agents / adverse effects*
  • Antipsychotic Agents / therapeutic use
  • Corpus Striatum / diagnostic imaging
  • Corpus Striatum / drug effects
  • Echoencephalography
  • Female
  • Humans
  • Image Enhancement
  • Image Processing, Computer-Assisted
  • Male
  • Middle Aged
  • Neural Pathways / diagnostic imaging
  • Neural Pathways / drug effects
  • Neurologic Examination / drug effects
  • Parkinson Disease, Secondary / chemically induced*
  • Parkinson Disease, Secondary / diagnosis
  • Psychotic Disorders / diagnostic imaging
  • Psychotic Disorders / drug therapy*
  • Risk Factors
  • Schizophrenia / diagnostic imaging
  • Schizophrenia / drug therapy*
  • Smoking
  • Substantia Nigra / diagnostic imaging
  • Substantia Nigra / drug effects

Substances

  • Antipsychotic Agents